Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;49(3):270-288.
doi: 10.1111/ceo.13917. Epub 2021 Mar 20.

Inherited retinal diseases: Therapeutics, clinical trials and end points-A review

Michalis Georgiou  1   2 , Kaoru Fujinami  1   2   3   4 , Michel Michaelides  1   2
Affiliations
Review

Inherited retinal diseases: Therapeutics, clinical trials and end points-A review

Michalis Georgiou et al. Clin Exp Ophthalmol. 2021 Apr.

Abstract

Inherited retinal diseases (IRDs) are a clinically and genetically heterogeneous group of disorders characterised by photoreceptor degeneration or dysfunction. These disorders typically present with severe vision loss that can be progressive, with disease onset ranging from congenital to late adulthood. The advances in genetics, retinal imaging and molecular biology, have conspired to create the ideal environment for establishing treatments for IRDs, with the first approved gene therapy and the commencement of multiple clinical trials. The scope of this review is to familiarise clinicians and scientists with the current management and the prospects for novel therapies for: (1) macular dystrophies, (2) cone and cone-rod dystrophies, (3) cone dysfunction syndromes, (4) Leber congenital amaurosis, (5) rod-cone dystrophies, (6) rod dysfunction syndromes and (7) chorioretinal dystrophies. We also briefly summarise the investigated end points for the ongoing trials.

Keywords: gene therapy; inherited retinal disease; pharmacological therapy; retina; stem cell.

PubMed Disclaimer

References

REFERENCES

    1. Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010. BMJ Open. 2014;4(2):e004015. https://doi.org/10.1136/bmjopen-2013-004015.
    1. Aboshiha J, Dubis AM, Carroll J, Hardcastle AJ, Michaelides M. The cone dysfunction syndromes. Br J Ophthalmol. 2016;100(1):115-121. https://doi.org/10.1136/bjophthalmol-2014-306505.
    1. Michaelides M, Hardcastle AJ, Hunt DM, Moore AT. Progressive cone and cone-rod dystrophies: phenotypes and underlying molecular genetic basis. Surv Ophthalmol. 2006;51(3):232-258. https://doi.org/10.1016/j.survophthal.2006.02.007.
    1. Pontikos N, Arno G, Jurkute N, et al. Genetic basis of inherited retinal disease in a molecularly characterised cohort of over 3000 families from the United Kingdom. Ophthalmology. 2020;127:1384-1394. https://doi.org/10.1016/j.ophtha.2020.04.008.
    1. Jacobson SG, Cideciyan AV, Ratnakaram R, et al. Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol. 2012;130(1):9-24. https://doi.org/10.1001/archophthalmol.2011.298.

LinkOut - more resources